Cryoport, Inc. (Nasdaq: CYRX), a Nashville, Tenn.-based global leader in temperature-controlled supply chain solutions for the life sciences industry, acquired Cell&Co BioServices, a Clermont-Ferrand, France-based bio services business with additional operations in Pont-du-Château, France.
Cryoport’s purchase price for Cell&Co was €6.2 million, comprised of an upfront consideration of €3.6 million in the form of cash and Cryoport common stock, plus a potential earn-out of €2.5M based on achieving certain financial targets.
Founded in 2012 by Sofien Dessolin and Florent Belon, Cell&Co is a bioservices business providing biorepository, kitting, and logistics services to the life sciences industry. It has been accredited by ISO 9001, ANSM, NFS 96 900 and ISO 20387. Supporting its biostorage and services of clinical and commercial biopharma therapies, Cell&Co has in-house QP services.
In 2021, Cell&Co recorded revenue of approximately €2.6 million.
Led by Jerrell Shelton, Chief Executive Officer, Cryoport is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene therapies across the clinical and commercial spectrum. Its global platform includes 33 strategically located locations that cover the Americas and EMEA (European, Middle East and Africa), and APAC (Asia Pacific). This platform provides mission-critical products, services and solutions to Biopharma, Animal Health and Reproductive Medicine customers all over the globe. In addition to its standard setting supply chain solutions, Cryoport is the world’s largest manufacturer of cryogenic systems and one of the largest life science-focused specialty couriers. Cryoport supported eight commercial cell- and gene therapies worldwide and 602 regenerative medicines clinical trials. There were 74 of those trials in Phase 3.